Newly designed targeted compounds for COVID-19, page-9

Long term...Biotron will need cash soon if they keep up the burn rate

This burn rate is also only R&D related and not HIV B225 Phase 2 or Phase 3 ralated...so without a massive cash injection there will be no real company value appreciation

BIT225 also seems to be mediocre...hence the reason they are 'Continuing the design, synthesis and testing of new compounds under its HIV-1 program, with the aim of identifying a next-generation lead anti-HIV-1 drug.'

They will need cash but who's going to give it to them...not me and not pharma any time soon

2c SEE YOU SOON